Abstract:Huntington disease (HD) is a progressive autosomal dominant neurodegenerative disorder in which patients typically present with uncontrolled involuntary movements and subsequent cognitive decline. In 1993, a CAG trinucleotide repeat expansion in the coding region of the huntingtin (HTT) gene was identified as the cause of this disorder. This extended CAG repeat results in production of HTT protein with an expanded polyglutamine tract, leading to pathogenic HTT protein conformers that are resistant to protein turnover, culminating in cellular toxicity and neurodegeneration. Research into the mechanistic basis of HD has highlighted a role for bioenergetics abnormalities stemming from mitochondrial dysfunction, and for synaptic defects, including impaired neurotransmission and excitotoxicity. Interference with transcription regulation may underlie the mitochondrial dysfunction. Current therapies for HD are directed at treating symptoms, as there are no disease-modifying therapies. Commonly prescribed drugs for involuntary movement control include tetrabenazine, a potent and selective inhibitor of vesicular monoamine transporter 2 that depletes synaptic monoamines, and olanzapine, an atypical neuroleptic that blocks the dopamine D2 receptor. Various drugs are used to treat non-motor features. The HD therapeutic pipeline is robust, as numerous efforts are underway to identify disease-modifying treatments, with some small compounds and biological agents moving into clinical trials. Especially encouraging are dosage reduction strategies, including antisense oligonucleotides, and molecules directed at transcription dysregulation. Given the depth and breadth of current HD drug development efforts, there is reason to believe that disease-modifying therapies for HD will emerge, and this achievement will have profound implications for the entire neurotherapeutics field.

Induced Pluripotent Stem Cells in Huntington’s Disease: Disease Modeling and the Potential for Cell-Based Therapy

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

Use of human stem cells in Huntington disease modeling and translational research

Induced neural stem cells as a means of treatment in Huntington’s disease

Neural Transplants from Human Induced Pluripotent Stem Cells Rescue the Pathology and Behavioral Defects in a Rodent Model of Huntington's Disease.

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases

Induced Pluripotent Stem Cells and Parkinson's Disease: Modelling and Treatment

Progress in studies of gene therapy for Huntington's disease

Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice

Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges

Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease

Human Induced Pluripotent Stem Cells in Parkinson's Disease: A Novel Cell Source of Cell Therapy and Disease Modeling

Human-induced pluripotent stem cells: potential for neurodegenerative diseases

Redefining Parkinson’s Disease Research Using Induced Pluripotent Stem Cells

Using induced pluripotent stem cells for modeling Parkinson's disease

Human cellular models of medium spiny neuron development and Huntington disease

Advances in the Application of Induced Pluripotent Stem Cells in Alzheimer's Disease and Parkinson's Disease

Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery

Therapy development in Huntington disease: From current strategies to emerging opportunities

Induced Pluripotent Stem Cells and Neurodegenerative Diseases

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease